8.1.5 Other antineoplastic drugs

• Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) - NICE TAG TA23
• Breast cancer - trastuzumab - NICE TAG TA34
• Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block- NICE TAG TA55
• Gastrointestinal stromal tumours - imatinib - NICE TAG TA86
• Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review) - NICE TAG TA91
• Prostate cancer (hormone-refractory) - docetaxel - NICE TAG TA101
• Breast cancer (early) - trastuzumab - NICE TAG TA107
• Breast cancer (early) - paclitaxel - NICE TAG TA108
• Breast cancer (early) - docetaxel - NICE TAG TA109
• Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer- NICE TAG TA118
• Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide - NICE TAG TA121
• Multiple myeloma - bortezomib - NICE TAG TA129
• Head and neck cancer - cetuximab - NICE TAG TA145
• Lung cancer (non-small-cell) - erlotinib - NICE TAG TA162
• Renal cell carcinoma - sunitinib - NICE TAG TA169
• Head and neck cancer (squamous cell carcinoma) - cetuximab - NICE TAG TA172
• Colorectal cancer (first line) - cetuximab - NICE TAG TA176
• Renal cell carcinoma - NICE TAG TA178
• Gastrointestinal stromal tumours - sunitinib - NICE TAG TA179
• Cervical cancer (recurrent) - topotecan - NICE TAG TA183
• Lung cancer (small-cell) - topotecan - NICE TAG TA184
• Soft tissue sarcoma - trabectedin - NICE TAG TA185
• Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) - NICE TAG TA189
• Lung cancer (non-small-cell, first line) - gefitinib - NICE TAG TA192
• Gastrointestinal stromal tumours - imatinib (adjuvant) - NICE TAG TA196
• Gastric cancer (HER2-positive metastatic) - trastuzumab - NICE TAG TA208
• Gastrointestinal stromal tumours (unresectable/metastatic) - imatinib - NICE TAG TA209
• Colorectal cancer (metastatic) - bevacizumab - NICE TAG TA212
• Breast cancer - bevacizumab (in combination with a taxane) - NICE TAG TA214
• Pazopanib for the first-line treatment of advanced renal cell carcinoma - NICE TAG TA215
• Everolimus for the second-line treatment of advanced renal cell carcinoma - NICE TAG TA219
• Ovarian cancer (relapsed) - trabectedin - NIE TAG TA222
• Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy) - NICE TAG TA227
• Multiple myeloma (first line) - bortezomib and thalidomide - NICE TAG TA228
• Leukaemia (chronic myeloid) - dasatinib, nilotinib, imatinib (intolerant, resistant) - NICE TAG TA241
• Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab - NICE TAG TA242
• Breast cancer (advanced) - eribulin - NICE TAG TA250
• Leukaemia (chronic myeloid, first line) - dasatanib, nilotinib and standard-dose imatinib - NICE TAG TA251
• Prostate cancer - cabazitazel - NICE TAG TA255
• Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) - NICE TAG TA257
• Lung cancer (non small cell, EGFR-TK mutation positive) - erlotinib (1st line) - NICE TAG TA258
• Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer - NICE TAG TA263
• Melanoma (stage III or IV) - ipilimumab - NICE TAG TA268
• Melanoma (BRAF V600 mutation positive, unresectable metastatic) – vemurafenib - NICE TAG TA269
• Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer - NICE TAG TA284
• Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab - NICE TAG TA285
• Myelofibrosis (splenomegaly, symptoms) - ruxolitinib - NICE TAG TA289
• Guidance on the use of imatinib for chronic myeloid leukaemia - NICE TAG TA70
• Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) - NICE TAG TA295
• Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib NICE TAG TA296
• Leukaemia (chronic myeloid) - bosutinib NICE TAG TA299
• Macular oedema (central retinal vein occlusion) - aflibercept solution for injection NICE TAG TA305
• Colorectal cancer (metastatic) - aflibercept NICE TAG TA307
• Lung cancer (non small cell, EGFR mutation positive) - afatinib NICE TAG TA310
• Multiple myeloma - bortezomib (induction therapy) NICE TAG TA311
• Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma - NICE TAG TA319
• Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma - NICE TAG TA321
• Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196) - NICE TAG TA326
• Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment - NICE TAG TA333
• Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab - NICE TAG TA357
• Ruxolitinib for treating polycythaemia vera (terminated appraisal) - NICE TAG 356
• Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) - NICE TAG TA353
• Aflibercept for treating diabetic macular oedema - NICE TAG TA346
• Everolimus for preventing organ rejection in liver transplantation - NICE TAG TA348
• Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer - NICE TAG TA347
• Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) - NICE TAG TA334
• Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) - NICE TAG TA328
• Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab - NICE TAG 357
• Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) - NICE TAG TA362
• Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer - NICE TAG TA360
• Idelalisib for treating chronic lymphocytic leukaemia - NICE TAG TA359
• Pembrolizumab for advanced melanoma not previously treated with ipilimumab - NICE TAG TA366
• Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane - NICE TAG TA371
• Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy - NICE TAG TA374
• Bortezomib for previously untreated mantle cell lymphoma - NICE TAG TA370
• Nintedanib for treating idiopathic pulmonary fibrosis - NICE TAG TA379
• Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy - NICE TAG TA378
• Panobinostat for treating multiple myeloma after at least 2 previous treatments - NICE TAG TA380
• Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy - NICE TAG TA381
• Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis - NICE TAG TA386
• Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer - NICE TAG TA389
• Nivolumab for treating advanced (unresectable or metastatic) melanoma - NICE TAG TA384
• Bosutinib for previously treated chronic myeloid leukaemia - NICE TAG TA401
• Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer - NICE TAG TA403
• Nivolumab in combination with ipilimumab for treating advanced melanoma - NICE TAG TA400
• Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma - NICE TAG TA396
• Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel - NICE TAG TA391
• Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer - NICE TAG TA395
• Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - NICE TAG TA406
• Pegaspargase for treating acute lymphoblastic leukaemia - NICE TAG TA408
• Talimogene laherparepvec for treating unresectable metastatic melanoma - NICE TAG TA410
• Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer - NICE TAG TA411
• Trifluridine–tipiracil for previously treated metastatic colorectal cancer - NICE TAG TA405
• Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma - NICE TAG TA414
• Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer - NICE TAG TA416
• Nivolumab for previously treated advanced renal cell carcinoma - NICE TAG TA417
• Everolimus with exemestane for treating advanced breast cancer after endocrine therapy - NICE TAG TA421
• Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer - NICE TAG TA422
• Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens - NICE TAG TA423
• Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer - NICE TAG TA424
• Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia - NICE TAG TA425
• Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia - NICE TAG TA426
• Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy- NICE TAG TA428
• Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine - NICE TAG TA440
• Cetuximab and panitumumab for previously untreated metastatic colorectal cancer - NICE TAG TA439
• Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation - NICE TAG TA429
• Everolimus for advanced renal cell carcinoma after previous treatment - NICE TAG TA432
• Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA462
• Carfilzomib for previously treated multiple myeloma - NICE TAG TA457
• Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane - NICE TAG TA458
• Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) - NICE TAG TA452
• Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) - NICE TAG TA453
• Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) - NICE TAG TA453
• Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma - NICE TAG TA446
• Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer - NICE TAG TA447
• Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease - NICE TAG TA449
• Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia - NICE TAG451
• Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal) - NICE TAG TA444
• Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine - NICE TAG TA440
• Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA540
• Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine - NICE TAG TA535
• Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) - NICE TAG TA469
• Cabozantinib for previously treated advanced renal cell carcinoma - NICE TAG TA463
• Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer - NICE TAG TA476
• Sorafenib for treating advanced hepatocellular carcinoma - NICE TAG TA474
• Ibrutinib for treating Waldenstrom’s macroglobulinaemia - NICE TAG TA491
• Vismodegib for treating basal cell carcinoma - NICE TAG TA489
• Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours - NICE TAG TA488
• Venetoclax for treating chronic lymphocytic leukaemia - NICE TAG TA487
• Ibrutinib for treating relapsed or refractory mantle cell lymphoma - NICE TAG TA502
• Ceritinib for untreated ALK-positive non-small-cell lung cancer - NICE TAG TA500
• Lenvatinib with everolimus for previously treated advanced renal cell carcinoma - NICE TAG TA498
• Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma - NICE TAG TA505
• Cabozantinib for treating medullary thyroid cancer - NICE TAG TA516
• Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen - NICE TAG TA515
• Regorafenib for previously treated advanced hepatocellular carcinoma - NICE TAG TA514
• Daratumumab monotherapy for treating relapsed and refractory multiple myeloma - NICE TAG TA510
• Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer - NICE TAG TA509
• Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy - NICE TAG TA519
• Avelumab for treating metastatic Merkel cell carcinoma - NICE TAG TA517
• Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy - NICE TAG TA520
• Arsenic trioxide for treating acute promyelocytic leukaemia - NICE TAG TA526
• Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy - NICE TAG TA525
• Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma - NICE TAG TA524
• Midostaurin for untreated acute myeloid leukaemia - NICE TAG TA523
• Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable - NICE TAG TA522
• Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer - NICE TAG TA531
• Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy - NICE TAG TA530
• Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer - NICE TAG TA529
• Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer - NIE TAG TA528
• Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours - NICE TAG TA539
• Dinutuximab beta for treating neuroblastoma - NICE TAG TA538
• Alectinib for untreated ALK-positive advanced non-small-cell lung cancer - NICE TAG TA536
• Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine - NICE TAG TA535
• Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia - NICE TAG TA541
• Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma - NICE TAG TA540
• Cabozantinib for untreated advanced renal cell carcinoma - NICE TAG TA542
• Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma - NICE TAG TA544
• Gemtuzumab ozogamicin for untreated acute myeloid leukaemia - NICE TAG TA545
• Vandetanib for treating medullary thyroid cancer - NICE TAG TA550
• Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer - NICE TAG TA557
• Regorafenib for previously treated advanced hepatocellular carcinoma - NICE TAG TA555
• Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence - NICE TAG TA553
• Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years - NICE TAG TA554
• Lenvatinib for untreated advanced hepatocellular carcinoma - NICE TAG TA551
• Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) - NICE TAG TA560
• Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) - NICE TAG TA 564
• Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer - NICE TAG TA563
• Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma - NICE TAG TA562
• Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia - NICE TAG TA561
• Bevacizumab with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer (terminated appraisal) - NICE TAG TA560
• Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib - NICE TAG TA571
• Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) - NICE TAG TA570
• Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer - NICE TAG TA569
• Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies - NICE TAG TA567
• Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies - NICE TA TAG567
• Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma - NICE TAG TA577
• Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) - NICE TAG TA576
• Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma - NICE TAG TA573
• Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) - NICE TAG TA582
• Nivolumab with ipilimumab for untreated advanced renal cell carcinoma - NICE TAG TA581
• Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy - NICE TAG TA579
• Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation - NICE TAG TA578
• Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer - NICE TAG TA584